TargetBeta
MC2R
melanocortin 2 receptor · also ACTHR · Melanocortin receptors
2 programs in company-led studies act on MC2R, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| atumelnantrule | Vertex Pharmaceuticals | phase 3 | 83 running | POMC | NCIt |
| OMS1620rule | OMass Therapeutics Australia Proprietary | phase 1 | 11 running | POMC | the studies' text |
Also acted on by the same programs
Conditions their studies are in
- Adrenal Hyperplasia, Congenital, 2 programs
- Cushing Syndrome, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- May 2027atumelnant · Vertex Pharmaceuticals · phase 3 · NCT07144163
- May 2027OMS1620 · OMass Therapeutics Australia Proprietary · phase 1 · NCT07811089
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.